CereVasc: Funding, Investors & Team (Sep 2026)
CereVasc specializes in creating new, less invasive medical devices for treating patients with neurological conditions. The current standard treatment for these patients involves a risky neurosurgical procedure with a lower success rate compared to other similar interventions. The eShunt System has the potential to greatly enhance patient outcomes and reduce the overall cost of treating this serious condition.
CereVasc has raised $155M across 2 funding rounds on record, the most recent a Series C of $85.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CereVasc Company Profile and Key Stats
Latest funding round on record: Jun 2026.
CereVasc Funding Rounds
CereVasc raised $70.0M in a Series B announced in May 2024.
2.1 years later, a Series C of $85.0M was announced in Jun 2026.
CereVasc Founders and Leadership Team
No contact details are on record for this team yet.
CereVasc Funding Compared to Other Biotechnology Startups
CereVasc's latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CereVasc in Biotechnology and Auburndale
Companies Similar to CereVasc
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
CereVasc Funding FAQs
What does CereVasc do?
CereVasc specializes in creating new, less invasive medical devices for treating patients with neurological conditions. The current standard treatment for these patients involves a risky neurosurgical procedure with a lower success rate compared to other similar interventions. The eShunt System has the potential to greatly enhance patient outcomes and reduce the overall cost of treating this serious condition.
How much funding has CereVasc raised?
CereVasc has raised $155M across 2 rounds on record. The most recent is a Series C of $85.0M announced in Jun 2026.
When did CereVasc last raise funding?
CereVasc's most recent funding round on record is a Series C of $85.0M, announced in Jun 2026.
Who founded CereVasc?
FundedIQ lists Adel Malek (Founder), Daniel Levangie (Founder) at CereVasc.
Where is CereVasc headquartered?
CereVasc is based in Auburndale, Massachusetts, United States.
How many employees does CereVasc have?
CereVasc is in the 11-50 employee band.
How does CereVasc's funding compare to other Biotechnology startups?
CereVasc's latest round of $85.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's CereVasc Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CereVasc is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.